Manufacturer and brand information of mirikizumab

Milikizumab(Mirikizumab) is an immunotherapy drug produced by global pharmaceutical company Eli Lilly and Company. Lilai is one of the world's leading pharmaceutical companies, committed to the research and development of innovative drugs, especially in the fields of diabetes, immunology, neurology and oncology, with deep technological accumulation.

Milizumab is a humanizedIgG4 monoclonal antibody that specifically binds to the p19 subunit of IL-23 to inhibit its binding to the receptor, thereby effectively blocking the IL-23 signaling pathway. This mechanism makes militizumab a powerful weapon in the treatment of chronic immune-mediated diseases such as ulcerative colitis (UC) and Crohn's disease (CD).

The drug development of Milizumab was completed on the basis of Lilai's long-term research on immune-mediated diseases. Through cooperation with many scientific research institutions around the world, Leilai has rapidly advanced the preclinical and clinical trials of militizumab, making it a biological agent with good efficacy and safety.

As an important product launched by Leilai, the brand name of Milikizumab directly uses its chemical nameMirikizumab, which is also the common name of the drug in the global market. Lelite hopes that through the launch of militizumab, it will further expand its influence in the field of immunotherapy and provide treatment options for more patients, especially in the fields of ulcerative colitis and Crohn's disease.

Milizumab's innovative and targeted nature makes it a very promising drug, especially in a world where treatment options for chronic inflammatory diseases are currently limited. With its launch and application in the international market, militizumab is expected to provide more efficient treatment options for patients around the world.

Keyword tags: Milizumab, Mirikizumab, levitra, biologics, IgG4 monoclonal antibody, ulcerative colitis, Crohn's disease, immunotherapy drugs

Reference materials:https://www.drugs.com/mirikizumab.html